EUCTR2008-008301-22-IT进行中（未招募）不适用
PHASE II CLINICAL STUDY OF THE DIAGNOSTIC EFFICACY OF [18F]FLUOROETHYILCHOLINE ([18F]FECh) IN PATIENTS WITH PROSTATE CANCER - ND
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点开始时间: 2009年1月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •-adult male patients with a) known prostate cancer (biopsy) and eligible for surgical treatment; b) biochemical recurrence of prostate cancer after prostatectomy (PSA> 0.2 ng/ml)
- •-availability to participate to the study (informed consent);
- •-patients suitable for the diagnostic procedure (PET-TC with 18F-FECh);
- •-patients with life expectancy > 2 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-patients not suitable for the study protocol;
- •-patients with life expectancy < 2 months
研究者
相似试验
尚未招募
2 期
Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide ReceptorMalignancies known to overexpress GRPR10027655CancerNL-OMON46627Advanced Accelerator Applications International S.A.10
进行中（未招募）
1 期
Study of [68Ga]-NeoBOMB1 imaging in patients with malignancies known to overexpress GRPRMalignancies known to overexpress Gastrin-Releasing Peptide ReceptorsMedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003432-37-ATAdvanced Accelerator Applications International SA50
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.EUCTR2019-001503-20-FRMedica Scientia Innovation Research (MedSIR)100
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001503-20-ITMEDICA SCIENTIA INNOVATION RESEARCH, ARO100
进行中（未招募）
1 期
Study to assess the efficacy and safety of the study drug atezolizumab in combination with paclitaxel and bevacizumab in patients with previously untreated advanced or metastatic triple negative breast cancer.Advanced or metastatic triple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2019-001503-20-DEMedica Scientia Innovation Research S. L. (MedSIR)100